Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07558395
Starting soon Not applicable

Effectiveness of a Visual Telerehabilitation Program on Visual Perception in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour

NCT07558395 · tracked via the Priya Life Science France tracker
Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Phase
Not applicable
Started
2026-12
Last updated
2026-09-16

Condition(s) studied

HemianopsiaVirtual RealityVisual RehabilitationPediatric Brain Tumor

Investigational drug(s) / intervention(s)

Visual Stimulationstandard of care

Visual Stimulation: Our audiovisual stimulation procedure IVR, called 3D-MOT, was encoded using the the 3D Unity programming platform and deployed in HMDs with built-in head/eye tracking. We implemented the multiple object tracking (MOT) paradigm, developed in the 80's to study visual attention in humans, and added correlated spatial sound.

standard of care: During this phase, the patients will be at home without a headset and will not be exposed to an audio-visual stimulation task in virtual reality.

Study summary

Evaluate the efficiency of audiovisual stimulation in virtual reality for improving the visual perception of children, adolescents, and young adults with hemianopia resulting from pediatric brain tumors. These individuals can lose up to 50% of their visual field, significantly impacting their independence, mobility, and daily lives.

Eligibility

Sex
ALL
Min age
10 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: * Male and Female * 10 - 40 years old * Diagnosed hemianopsia (\>12 months) * History of diagnosis brain tumour * Being stable for the tumour for \> 6 months (either on therapy or not) * Visual acuity ≤ 0.7 LogMAR * Ability to follow the visual and auditory stimuli and training instructions * Home WiFi access * Ability to attend all on site visits * Affiliation to the Social Security or beneficiary of such social protection Exclusion Criteria: * Age\< 10 years old of \> 40 years old * Ocular disease * Inability to perform during testing or training * 3 consecutive VRISE scores \< 25 at inclusion * History of vertigo * Prior vision rehabilitation interventions * Recreational or medicinal consumption of psychoactive drugs * Persons under court protection * Interpupillary distance \< 54mm

Primary outcome measure(s)

  • Visual field perimetry measured using the Esterman binocular field test — From enrollment to the end of follow up period at 6 months
    Increase at least 3 points in the number of points perceived in the blind field at the Esterman binocular field test after intervention (8 weeks) when compared to baseline and between control and interventional group.

Trial sites (8)

FacilityCityRegionStatus
Department of Paediatric and adolescents medicine, Medical University Vienna Austria
Paediatrics and Adolescents Medicine, University Hospital Copenhagen Denmark
Hôpital de Hautepierre Strasbourg France
Institute of Tumour, department of haematology and Oncohaematology paediatric Milan Italy
Paediatric Haematology, University Hospital Padova Italy
Princess Maxima Centre for Paediatric Oncology Utrecht Netherlands
Paediatric Oncology, San Joan de Deu Barcelona Spain
Great Ormond Street Hospital for Children London United Kingdom

More Institut National de la Santé Et de la Recherche Médicale, France trials in France

European Cystinosis Cohort 2 Starting soon
MPS (RaDiCo Cohort) (RaDiCo-MPS) Recruiting
CHronic Hepatopathies Associated With ALcohol Consumption aNd metAbolic Syndrome Recruiting
X-linked Moesin Associated Immunodeficiency Recruiting
Cerebello-motor Neuromodulation After Stroke. CERSTIM. Recruiting

Other trials for the same condition

Virtual Reality for Children in Radiotherapy (REVER) Recruiting
Use of Virtual Reality as a Tool for Cognitive Remediation in Elderly Depressed Patients Starting soon
Dynamic Balance in Unilateral Transtibial Amputees Following Virtual Reality Versus Conventional Rehabilitation Recruiting
Pain Management With Virtual Reality Hypnosis Recruiting
Evaluation of the Effectiveness of Virtual Reality Self-rehabilitation in the Treatment of Facial Paralysis and Synkinesis Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07558395 on ClinicalTrials.gov ↗ ← All trials in France